Amyloid biomarkers in Alzheimer's disease

Trends in Pharmacological Sciences

Volumn 36, Issue 5, 2015, Pages 297-309

  Blennow, Kaj ^a,b   Mattsson, Niklas ^a,c,d   Schöll, Michael ^a,e   Hansson, Oskar ^f   Zetterberg, Henrik ^a,g  

^a UNIVERSITY OF GOTHENBURG   (Sweden)

^b ROYAL SWEDISH ACADEMY OF SCIENCES   (Sweden)

^c SAN FRANCISCO VETERANS AFFAIRS MEDICAL CENTER   (United States)

^d UNIVERSITY OF CALIFORNIA   (United States)

^e UNIVERSITY OF CALIFORNIA   (United States)

^f LUND UNIVERSITY   (Sweden)

^g UNIVERSITY COLLEGE LONDON   (United Kingdom)

Author keywords

Alzheimer's disease; biomarker; cerebrospinal fluid; positron emission tomography (PET); amyloid (A )

Indexed keywords

AMYLOID BETA PROTEIN; AMYLOID BETA-PROTEIN (1-42); BIOLOGICAL MARKER; PEPTIDE FRAGMENT;

ALZHEIMER DISEASE; ANIMAL; CEREBROSPINAL FLUID; HUMAN; POSITRON EMISSION TOMOGRAPHY; SCINTISCANNING; STANDARD; STANDARDS;

ALZHEIMER DISEASE; AMYLOID BETA-PEPTIDES; ANIMALS; BIOLOGICAL MARKERS; HUMANS; PEPTIDE FRAGMENTS; POSITRON-EMISSION TOMOGRAPHY; REFERENCE STANDARDS;

EID: 84937758712     PISSN: 01656147     EISSN: 18733735     Source Type: Journal    
DOI: 10.1016/j.tips.2015.03.002     Document Type: Article

References (140)

1. G.G. Glenner Amyloid deposits and amyloidosis. The beta-fibrilloses (first of two parts) N. Engl. J. Med. 302 1980 1283 1292
2. K. Blennow et al. Alzheimer's disease Lancet 368 2006 387 403
3. J. Hardy The amyloid hypothesis for Alzheimer's disease: a critical reappraisal J. Neurochem. 110 2009 1129 1134
4. K. Blennow et al. Biomarkers in amyloid-beta immunotherapy trials in Alzheimer's disease Neuropsychopharmacology 39 2014 189 201
5. S. Salloway et al. Two phase 3 trials of bapineuzumab in mild-to-moderate Alzheimer's disease N. Engl. J. Med. 370 2014 322 333
6. R.S. Doody et al. A phase 3 trial of semagacestat for treatment of Alzheimer's disease N. Engl. J. Med. 369 2013 341 350
7. R.S. Doody et al. Phase 3 trials of solanezumab for mild-to-moderate Alzheimer's disease N. Engl. J. Med. 370 2014 311 321
8. E. Karran, and J. Hardy Antiamyloid therapy for Alzheimer's disease - are we on the right road? N. Engl. J. Med. 370 2014 377 378
9. K. Blennow Biomarkers in Alzheimer's disease drug development Nat. Med. 16 2010 1218 1222
10. K. Blennow et al. Cerebrospinal fluid and plasma biomarkers in Alzheimer disease Nat. Rev. Neurol. 6 2010 131 144
11. L. Lannfelt et al. Safety, efficacy, and biomarker findings of PBT2 in targeting Abeta as a modifying therapy for Alzheimer's disease: a phase IIa, double-blind, randomised, placebo-controlled trial Lancet Neurol. 7 2008 779 786
12. B. Winblad et al. Safety, tolerability, and antibody response of active Abeta immunotherapy with CAD106 in patients with Alzheimer's disease: randomised, double-blind, placebo-controlled, first-in-human study Lancet Neurol. 11 2012 597 604
13. P.C. May et al. Robust central reduction of amyloid-beta in humans with an orally available, non-peptidic beta-secretase inhibitor J. Neurosci. 31 2011 16507 16516
14. H. Hampel et al. Biomarkers for Alzheimer's disease: academic, industry and regulatory perspectives Nat. Rev. Drug Discov. 9 2010 560 574
15. Biomarkers Definitions Working Group Biomarkers and surrogate endpoints: preferred definitions and conceptual framework Clin. Pharmacol. Ther. 69 2001 89 95
16. Anon Consensus report of the Working Group on: 'Molecular and Biochemical Markers of Alzheimer's Disease'. The Ronald and Nancy Reagan Research Institute of the Alzheimer's Association and the National Institute on Aging Working Group Neurobiol. Aging 19 1998 109 116
17. E. Portelius et al. A novel pathway for amyloid precursor protein processing Neurobiol. Aging 32 2011 1090 1098
18. H. Zetterberg et al. Elevated cerebrospinal fluid BACE1 activity in incipient Alzheimer disease Arch. Neurol. 65 2008 1102 1107
19. M. Holtta et al. Evaluating amyloid-beta oligomers in cerebrospinal fluid as a biomarker for Alzheimer's disease PLoS ONE 8 2013 e66381
20. M.J. Savage et al. A sensitive abeta oligomer assay discriminates Alzheimer's and aged control cerebrospinal fluid J. Neurosci. 34 2014 2884 2897
21. C. Haass et al. Amyloid beta-peptide is produced by cultured cells during normal metabolism Nature 359 1992 322 325
22. M. Tabaton et al. Soluble amyloid beta-protein is a marker of Alzheimer amyloid in brain but not in cerebrospinal fluid Biochem. Biophys. Res. Commun. 200 1994 1598 1603
23. W.E. Van Nostrand et al. Decreased levels of soluble amyloid beta-protein precursor in cerebrospinal fluid of live Alzheimer disease patients Proc. Natl. Acad. Sci. U.S.A. 89 1992 2551 2555
24. T. Iwatsubo et al. Visualization of A beta 42(43) and A beta 40 in senile plaques with end-specific A beta monoclonals: evidence that an initially deposited species is A beta 42(43) Neuron 13 1994 45 53
25. J.T. Jarrett et al. The carboxy terminus of the beta amyloid protein is critical for the seeding of amyloid formation: implications for the pathogenesis of Alzheimer's disease Biochemistry 32 1993 4693 4697
26. R. Motter et al. Reduction of beta-amyloid peptide42 in the cerebrospinal fluid of patients with Alzheimer's disease Ann. Neurol. 38 1995 643 648
27. K. Blennow, and H. Hampel CSF markers for incipient Alzheimer's disease Lancet Neurol. 2 2003 605 613
28. N. Andreasen et al. Cerebrospinal fluid beta-amyloid(1-42) in Alzheimer disease: differences between early- and late-onset Alzheimer disease and stability during the course of disease Arch. Neurol. 56 1999 673 680
29. A. Olsson et al. Simultaneous measurement of beta-amyloid(1-42), total tau, and phosphorylated tau (Thr181) in cerebrospinal fluid by the xMAP technology Clin. Chem. 51 2005 336 345
30. J. Wiltfang et al. Highly conserved and disease-specific patterns of carboxyterminally truncated Abeta peptides 1-37/38/39 in addition to 1-40/42 in Alzheimer's disease and in patients with chronic neuroinflammation J. Neurochem. 81 2002 481 496
31. A. Leinenbach et al. Mass spectrometry-based candidate reference measurement procedure for quantification of amyloid-beta in cerebrospinal fluid Clin. Chem. 60 2014 987 994
32. K. Blennow, and E. Vanmechelen CSF markers for pathogenic processes in Alzheimer's disease: diagnostic implications and use in clinical neurochemistry Brain Res. Bull. 61 2003 235 242
33. E. Portelius et al. Determination of beta-amyloid peptide signatures in cerebrospinal fluid using immunoprecipitation-mass spectrometry J. Proteome Res. 5 2006 1010 1016
34. O. Hansson et al. Prediction of Alzheimer's disease using the CSF Abeta42/Abeta40 ratio in patients with mild cognitive impairment Dement. Geriatr. Cogn. Disord. 23 2007 316 320
35. P. Lewczuk et al. Amyloid-beta 42/40 cerebrospinal fluid concentration ratio in the diagnostics of Alzheimer's disease: validation of two novel assays J. Alzheimers Dis. 43 2015 183 191
36. P.D. Mehta et al. Plasma and cerebrospinal fluid levels of amyloid beta proteins 1-40 and 1-42 in Alzheimer disease Arch. Neurol. 57 2000 100 105
37. J. Wiltfang et al. Amyloid beta peptide ratio 42/40 but not A beta 42 correlates with phospho-Tau in patients with low- and high-CSF A beta 40 load J. Neurochem. 101 2007 1053 1059
38. W.E. Klunk et al. Imaging brain amyloid in Alzheimer's disease with Pittsburgh Compound-B Ann. Neurol. 55 2004 306 319
39. C.R. Jack Jr et al. Cerebral amyloid PET imaging in Alzheimer's disease Acta Neuropathol. 126 2013 643 657
40. W.E. Klunk Amyloid imaging as a biomarker for cerebral beta-amyloidosis and risk prediction for Alzheimer dementia Neurobiol. Aging 32 Suppl. 1 2011 S20 S36
41. D.F. Wong et al. In vivo imaging of amyloid deposition in Alzheimer disease using the radioligand 18F-AV-45 (florbetapir [corrected] F 18) J. Nucl. Med. 51 2010 913 920
42. N. Nelissen et al. Phase 1 study of the Pittsburgh compound B derivative 18F-flutemetamol in healthy volunteers and patients with probable Alzheimer disease J. Nucl. Med. 50 2009 1251 1259
43. C.C. Rowe et al. Imaging of amyloid beta in Alzheimer's disease with 18F-BAY94-9172, a novel PET tracer: proof of mechanism Lancet Neurol. 7 2008 129 135
44. C.C. Rowe et al. Head-to-head comparison of 11C-PiB and 18F-AZD4694 (NAV4694) for beta-amyloid imaging in aging and dementia J. Nucl. Med. 54 2013 880 886
45. A. Lockhart et al. PIB is a non-specific imaging marker of amyloid-beta (Abeta) peptide-related cerebral amyloidosis Brain 130 2007 2607 2615
46. M.D. Ikonomovic et al. Post-mortem correlates of in vivo PiB-PET amyloid imaging in a typical case of Alzheimer's disease Brain 131 2008 1630 1645
47. B.J. Bacskai et al. Molecular imaging with Pittsburgh Compound B confirmed at autopsy: a case report Arch. Neurol. 64 2007 431 434
48. M. Scholl et al. Low PiB PET retention in presence of pathologic CSF biomarkers in Arctic APP mutation carriers Neurology 79 2012 229 236
49. S.M. Greenberg et al. Detection of isolated cerebrovascular beta-amyloid with Pittsburgh compound B Ann. Neurol. 64 2008 587 591
50. J.V. Ly et al. 11C-PIB binding is increased in patients with cerebral amyloid angiopathy-related hemorrhage Neurology 74 2010 487 493
51. C.M. Clark et al. Use of florbetapir-PET for imaging beta-amyloid pathology JAMA 305 2011 275 283
52. C.M. Clark et al. Cerebral PET with florbetapir compared with neuropathology at autopsy for detection of neuritic amyloid-beta plaques: a prospective cohort study Lancet Neurol. 11 2012 669 678
53. J.O. Rinne et al. [(18)F]Flutemetamol PET imaging and cortical biopsy histopathology for fibrillar amyloid beta detection in living subjects with normal pressure hydrocephalus: pooled analysis of four studies Acta Neuropathol. 124 2012 833 845
54. V. Leinonen et al. Diagnostic effectiveness of quantitative [(1)(8)F]flutemetamol PET imaging for detection of fibrillar amyloid beta using cortical biopsy histopathology as the standard of truth in subjects with idiopathic normal pressure hydrocephalus Acta Neuropathol. Commun. 2 2014 46
55. D. Strozyk et al. CSF Abeta 42 levels correlate with amyloid-neuropathology in a population-based autopsy study Neurology 60 2003 652 656
56. T. Tapiola et al. Cerebrospinal fluid {beta}-amyloid 42 and tau proteins as biomarkers of Alzheimer-type pathologic changes in the brain Arch. Neurol. 66 2009 382 389
57. B. Mollenhauer et al. Different CSF beta-amyloid processing in Alzheimer's and Creutzfeldt-Jakob disease J. Neural Transm. 118 2011 691 697
58. A.M. Fagan et al. Inverse relation between in vivo amyloid imaging load and cerebrospinal fluid Abeta42 in humans Ann. Neurol. 59 2006 512 519
59. A.M. Fagan et al. Cerebrospinal fluid tau/beta-amyloid(42) ratio as a prediction of cognitive decline in nondemented older adults Arch. Neurol. 64 2007 343 349
60. A.M. Fagan et al. Cerebrospinal fluid tau and ptau(181) increase with cortical amyloid deposition in cognitively normal individuals: implications for future clinical trials of Alzheimer's disease EMBO Mol. Med. 1 2009 371 380
61. A. Forsberg et al. PET imaging of amyloid deposition in patients with mild cognitive impairment Neurobiol. Aging 29 2008 1456 1465
62. W.J. Jagust et al. Relationships between biomarkers in aging and dementia Neurology 73 2009 1193 1199
63. N. Tolboom et al. Relationship of cerebrospinal fluid markers to 11C-PiB and 18F-FDDNP binding J. Nucl. Med. 50 2009 1464 1470
64. M. Degerman Gunnarsson et al. Pittsburgh compound-B and Alzheimer's disease biomarkers in CSF, plasma and urine: An exploratory study Dement. Geriatr. Cogn. Disord. 29 2010 204 212
65. S.D. Weigand et al. Transforming cerebrospinal fluid Abeta42 measures into calculated Pittsburgh Compound B units of brain Abeta amyloid Alzheimers Dement. 7 2011 133 141
66. M. Zwan et al. Concordance between cerebrospinal fluid biomarkers and [11C]PIB PET in a memory clinic cohort J. Alzheimers Dis. 41 2014 801 807
67. S.M. Landau et al. Comparing positron emission tomography imaging and cerebrospinal fluid measurements of beta-amyloid Ann. Neurol. 74 2013 826 836
68. S. Palmqvist et al. Accuracy of brain amyloid detection in clinical practice using cerebrospinal fluid beta-amyloid 42: a cross-validation study against amyloid positron emission tomography JAMA Neurol. 71 2014 1282 1289
69. E. Portelius et al. Mass spectrometric characterization of brain amyloid beta isoform signatures in familial and sporadic Alzheimer's disease Acta Neuropathol. 120 2010 185 193
70. H. Hampel et al. Total and phosphorylated tau protein as biological markers of Alzheimer's disease Exp. Gerontol. 45 2010 30 40
71. N.J. Cairns et al. Absence of Pittsburgh compound B detection of cerebral amyloid beta in a patient with clinical, cognitive, and cerebrospinal fluid markers of Alzheimer disease: a case report Arch. Neurol. 66 2009 1557 1562
72. N. Mattsson et al. Independent information from cerebrospinal fluid amyloid-beta and florbetapir imaging in Alzheimer's disease Brain 138 2015 772 783
73. Y. Su et al. Quantitative analysis of PiB-PET with FreeSurfer ROIs PLoS ONE 8 2013 e73377
74. N. Mattsson et al. Diagnostic accuracy of CSF Ab42 and florbetapir PET for Alzheimer's disease Ann. Clin. Transl. Neurol. 1 2014 534 543
75. L.M. Shaw et al. Cerebrospinal fluid biomarker signature in Alzheimer's disease neuroimaging initiative subjects Ann. Neurol. 65 2009 403 413
76. N. Mattsson et al. CSF biomarkers and incipient Alzheimer disease in patients with mild cognitive impairment JAMA 302 2009 385 393
77. M.C. Carrillo et al. Global standardization measurement of cerebral spinal fluid for Alzheimer's disease: an update from the Alzheimer's Association Global Biomarkers Consortium Alzheimers Dement. 9 2013 137 140
78. M. Korecka et al. Qualification of a surrogate matrix-based absolute quantification method for amyloid-beta(4)(2) in human cerebrospinal fluid using 2D UPLC-tandem mass spectrometry J. Alzheimers Dis. 41 2014 441 451
79. N. Mattsson et al. Reference measurement procedures for Alzheimer's disease cerebrospinal fluid biomarkers: definitions and approaches with focus on amyloid beta42 Biomark. Med. 6 2012 409 417
80. N. Mattsson et al. The Alzheimer's Association external quality control program for cerebrospinal fluid biomarkers Alzheimers Dement. 7 2011 386 395
81. J.A. Thie Understanding the standardized uptake value, its methods, and implications for usage J. Nucl. Med. 45 2004 1431 1434
82. M.A. Mintun et al. A quantitative model for the in vivo assessment of drug binding sites with positron emission tomography Ann. Neurol. 15 1984 217 327
83. J. Koivunen et al. PET amyloid ligand [11C]PIB uptake shows predominantly striatal increase in variant Alzheimer's disease Brain 131 2008 1845 1853
84. P. Edison et al. Can target-to-pons ratio be used as a reliable method for the analysis of [11C]PIB brain scans? Neuroimage 60 2012 1716 1723
85. W.E. Klunk et al. The centiloid project: standardizing quantitative amyloid plaque estimation by PET Alzheimers Dement. 11 2015 1 15
86. G.B. Frisoni et al. Imaging markers for Alzheimer disease: which vs how Neurology 81 2013 487 500
87. A. Okello et al. Conversion of amyloid positive and negative MCI to AD over 3 years: an 11C-PIB PET study Neurology 73 2009 754 760
88. C.R. Jack Jr et al. Brain beta-amyloid measures and magnetic resonance imaging atrophy both predict time-to-progression from mild cognitive impairment to Alzheimer's disease Brain 133 2010 3336 3348
89. O. Hansson et al. Association between CSF biomarkers and incipient Alzheimer's disease in patients with mild cognitive impairment: a follow-up study Lancet Neurol. 5 2006 228 234
90. P.J. Visser et al. Prevalence and prognostic value of CSF markers of Alzheimer's disease pathology in patients with subjective cognitive impairment or mild cognitive impairment in the DESCRIPA study: a prospective cohort study Lancet Neurol. 8 2009 619 627
91. R. Perry et al. Lewy body dementia: clinical, pathological and neurochemical interconnections J. Neural Transm. Suppl. 51 1997 95 109
92. C. Ballard et al. Differences in neuropathologic characteristics across the Lewy body dementia spectrum Neurology 67 2006 1931 1934
93. P. Edison et al. Amyloid load in Parkinson's disease dementia and Lewy body dementia measured with [11C]PIB positron emission tomography J. Neurol. Neurosurg. Psychiatry 79 2008 1331 1338
94. S.N. Gomperts et al. Imaging amyloid deposition in Lewy body diseases Neurology 71 2008 903 910
95. L. Parnetti et al. Cerebrospinal fluid biomarkers in Parkinson's disease with dementia and dementia with Lewy bodies Biol. Psychiatry 64 2008 850 855
96. W. Maetzler et al. Cortical PIB binding in Lewy body disease is associated with Alzheimer-like characteristics Neurobiol. Dis. 34 2009 107 112
97. S. Hall et al. Accuracy of a panel of 5 cerebrospinal fluid biomarkers in the differential diagnosis of patients with dementia and/or parkinsonian disorders Arch. Neurol. 69 2012 1445 1452
98. M. Lehmann et al. Diverging patterns of amyloid deposition and hypometabolism in clinical variants of probable Alzheimer's disease Brain 136 2013 844 858
99. T.P. Baumann et al. CSF-tau and CSF-Abeta(1-42) in posterior cortical atrophy Dement. Geriatr. Cogn. Disord. 29 2010 530 533
100. L.C. de Souza et al. Cerebrospinal fluid biomarkers in the differential diagnosis of Alzheimer's disease from other cortical dementias J. Neurol. Neurosurg. Psychiatry 82 2011 240 246
101. J. Seguin et al. CSF biomarkers in posterior cortical atrophy Neurology 76 2011 1782 1788
102. M. Otto et al. Decreased beta-amyloid1-42 in cerebrospinal fluid of patients with Creutzfeldt-Jakob disease Neurology 54 2000 1099 1102
103. B. Van Everbroeck et al. A prospective study of CSF markers in 250 patients with possible Creutzfeldt-Jakob disease J. Neurol. Neurosurg. Psychiatry 74 2003 1210 1214
104. G. Zanusso et al. Cerebrospinal fluid markers in sporadic Creutzfeldt-Jakob disease Int. J. Mol. Sci. 12 2011 6281 6292
105. H. Hyare et al. 11C-PiB PET does not detect PrP-amyloid in prion disease patients including variant Creutzfeldt-Jakob disease J. Neurol. Neurosurg. Psychiatry 83 2012 340 341
106. V.L. Villemagne et al. 11C-PiB PET studies in typical sporadic Creutzfeldt-Jakob disease J. Neurol. Neurosurg. Psychiatry 80 2009 998 1001
107. J.J. Krut et al. Cerebrospinal fluid Alzheimer's biomarker profiles in CNS infections J. Neurol. 260 2013 620 626
108. M. Sjogren et al. Low cerebrospinal fluid beta-amyloid 42 in patients with acute bacterial meningitis and normalization after treatment Neurosci. Lett. 314 2001 33 36
109. N. Mattsson et al. Neuroinflammation in Lyme neuroborreliosis affects amyloid metabolism BMC Neurol. 10 2010 51
110. B.J. Brew et al. CSF amyloid beta42 and tau levels correlate with AIDS dementia complex Neurology 65 2005 1490 1492
111. E. Trysberg et al. Decreased levels of soluble amyloid beta-protein precursor and beta-amyloid protein in cerebrospinal fluid of patients with systemic lupus erythematosus Arthritis Res. Ther. 6 2004 R129 R136
112. N. Mattsson et al. Reduced cerebrospinal fluid BACE1 activity in multiple sclerosis Mult. Scler. 15 2009 448 454
113. F. Mori et al. Cognitive and cortical plasticity deficits correlate with altered amyloid-beta CSF levels in multiple sclerosis Neuropsychopharmacology 36 2011 559 568
114. K. Augutis et al. Cerebrospinal fluid biomarkers of beta-amyloid metabolism in multiple sclerosis Mult. Scler. 19 2013 543 552
115. M. Gisslen et al. Amyloid and tau cerebrospinal fluid biomarkers in HIV infection BMC Neurol. 9 2009 63
116. W. Mai et al. Cerebrospinal fluid levels of soluble amyloid precursor protein and beta-amyloid 42 in patients with multiple sclerosis, neuromyelitis optica and clinically isolated syndrome J. Int. Med. Res. 39 2011 2402 2413
117. L. Szalardy et al. Evaluating biomarkers of neuronal degeneration and neuroinflammation in CSF of patients with multiple sclerosis-osteopontin as a potential marker of clinical severity J. Neurol. Sci. 331 2013 38 42
118. S.T. DeKosky et al. Acute and chronic traumatic encephalopathies: pathogenesis and biomarkers Nat. Rev. Neurol. 9 2013 192 200
119. V.E. Johnson et al. Traumatic brain injury and amyloid-beta pathology: a link to Alzheimer's disease? Nat. Rev. Neurosci. 11 2010 361 370
120. D.I. Graham et al. Distribution of beta-amyloid protein in the brain following severe head injury Neuropathol. Appl. Neurobiol. 21 1995 27 34
121. G.W. Roberts et al. beta A4 amyloid protein deposition in brain after head trauma Lancet 338 1991 1422 1423
122. D.H. Smith et al. Amyloid beta accumulation in axons after traumatic brain injury in humans J. Neurosurg. 98 2003 1072 1077
123. M.D. Ikonomovic et al. Alzheimer's pathology in human temporal cortex surgically excised after severe brain injury Exp. Neurol. 190 2004 192 203
124. Y.T. Hong et al. Amyloid imaging with carbon 11-labeled Pittsburgh compound B for traumatic brain injury JAMA Neurol. 71 2014 23 31
125. A. Olsson et al. Marked increase of beta-amyloid(1-42) and amyloid precursor protein in ventricular cerebrospinal fluid after severe traumatic brain injury J. Neurol. 251 2004 870 876
126. B. Dubois et al. Advancing research diagnostic criteria for Alzheimer's disease: the IWG-2 criteria Lancet Neurol. 13 2014 614 629
127. G.M. McKhann et al. The diagnosis of dementia due to Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease Alzheimers Dement. 7 2011 263 269
128. M.S. Albert et al. The diagnosis of mild cognitive impairment due to Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease Alzheimers Dement. 7 2011 270 279
129. C. Valcarcel-Nazco et al. Cost-effectiveness of the use of biomarkers in cerebrospinal fluid for Alzheimer's disease J. Alzheimers Dis. 42 2014 777 788
130. K. Blennow et al. Low frequency of post-lumbar puncture headache in demented patients Acta Neurol. Scand. 88 1993 221 223
131. E. Peskind et al. Safety of lumbar puncture procedures in patients with Alzheimer's disease Curr. Alzheimer Res. 6 2009 290 292
132. E.R. Peskind et al. Safety and acceptability of the research lumbar puncture Alzheimer Dis. Assoc. Disord. 19 2005 220 225
133. H. Zetterberg et al. Low incidence of post-lumbar puncture headache in 1,089 consecutive memory clinic patients Eur. Neurol. 63 2010 326 330
134. D. Alcolea et al. Feasibility of lumbar puncture in the study of cerebrospinal fluid biomarkers for Alzheimer's disease: a multicenter study in Spain J. Alzheimers Dis. 39 2014 719 726
135. C.R. Jack Jr et al. Hypothetical model of dynamic biomarkers of the Alzheimer's pathological cascade Lancet Neurol. 9 2010 119 128
136. C.R. Jack Jr et al. Tracking pathophysiological processes in Alzheimer's disease: an updated hypothetical model of dynamic biomarkers Lancet Neurol. 12 2013 207 216
137. R.J. Bateman et al. Clinical and biomarker changes in dominantly inherited Alzheimer's disease N. Engl. J. Med. 367 2012 795 804
138. E.R. Zimmer et al. Developments in Tau PET Imaging Can. J. Neurol. Sci. 41 2014 547 553
139. A. Brinkmalm et al. SNAP-25 is a promising novel cerebrospinal fluid biomarker for synapse degeneration in Alzheimer's disease Mol. Neurodegener. 9 2014 53
140. H. Kvartsberg et al. Cerebrospinal fluid levels of the synaptic protein neurogranin correlates with cognitive decline in prodromal Alzheimer's disease Alzheimers Dement. 2014 10.1016/j.jalz.2014.10.009 Published December 19, 2014